AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20399668 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa)
Number of subjects: 5
Study 20399668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 17440520 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt supplement containing L. acidophilus 74-2 and B. lactis 420 (300 g/day)
Number of subjects: 26
Study 17440520 — intervention group
Group type: COMPARATOR
Intervention: Placebo product
Number of subjects: 26
Study 17242812 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic agents, anticonvulsants, opioids, benzodiazepines, zolpidem, entacapone, ketamine
Number of subjects: 0
Study 17242812 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron
Number of subjects: 0
Study 17242812 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin and L-dopa (sustained release formulation)
Number of subjects: 0
Study 12527491 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 98
Study 12527491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 12527491 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream vs Placebo
Number of subjects: 98
Study 10212103 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (500 microg twice daily) for four weeks
Number of subjects: 25
Study 10212103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8729126 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids
Number of subjects: 0
Study 8729126 — intervention group
Group type: COMPARATOR
Intervention: steroids and other immunosuppressive agents (e.g., cyclosporin A)
Number of subjects: 0
Study 1422714 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 per cent lignocaine (n = 19)
Number of subjects: 34
Study 1422714 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (n = 21)
Number of subjects: 34
Study 4046122 — intervention group
Group type: EXPERIMENTAL
Intervention: Total WBC count
Number of subjects: 6222
Study 4046122 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in WBC count from baseline to annual examination
Number of subjects: 6222
Study 4046122 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC count
Number of subjects: 6222
Study 30140328 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Brief Pain Inventory worst pain severity (m-BPI-WPS)
Number of subjects: 452
Study 30140328 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Global Impression of Change (PGIC)
Number of subjects: 452
Study 27346176 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vitamin K oral anticoagulants (NOACs)
Number of subjects: 71683
Study 27346176 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose edoxaban
Number of subjects: 71683
Study 27346176 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose edoxaban
Number of subjects: 71683
Study 27346176 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 71683
Study 24618935 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric antibiotic therapy in FN episodes with bacteremia
Number of subjects: 441
Study 24618935 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MDI
Number of subjects: 441
Study 22142823 — intervention group
Group type: EXPERIMENTAL
Intervention: High T(ccr7) tumor infiltration
Number of subjects: 76
Study 22142823 — intervention group
Group type: EXPERIMENTAL
Intervention: High T(ccr7) and T(reg) tumor infiltration
Number of subjects: 76
Study 20549832 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus 10 mg/d
Number of subjects: 416
Study 20549832 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 416
Study 17490788 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated diagnostic protocol
Number of subjects: 149
Study 16206600 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril + trimetazidine
Number of subjects: 64
Study 16206600 — intervention group
Group type: COMPARATOR
Intervention: Enalapril + placebo
Number of subjects: 64
Study 12410482 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from protease inhibitors to alternative drugs
Number of subjects: 0
Study 12410482 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching thymidine analogue reverse-transcriptase inhibitors
Number of subjects: 0
Study 12410482 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitution of other agents for protease inhibitors
Number of subjects: 0
Study 12410482 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10190874 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (2.5 mg IV in 5 minutes)
Number of subjects: 14
Study 10190874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7571745 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in structured quality circles
Number of subjects: 25
Study 7571745 — intervention group
Group type: COMPARATOR
Intervention: Control group without peer review
Number of subjects: 25
Study 2376378 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunomycin applied to the vitreous cavity during pars plana vitrectomy (PPV)
Number of subjects: 14
Study 2376378 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with PPV and silicone tamponade alone
Number of subjects: 14
Study 7317666 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide (NO2) exposure (207 micrograms/m3)
Number of subjects: 7
Study 7317666 — intervention group
Group type: COMPARATOR
Intervention: Unpolluted air exposure
Number of subjects: 7
Study 30168611 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) mediated by methylene blue and red laser diode (Periowave®, λ = 670 nm, 200 mW)
Number of subjects: 40
Study 30168611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) based on 10 pulses/cm2 (Dye-VL-F module, Alma Lasers, λ = 500-600 nm, 10 J)
Number of subjects: 40
Study 27839954 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 198
Study 27839954 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 198
Study 26101179 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrigid, inelastic lumbar brace (worn for 2 weeks)
Number of subjects: 54
Study 25147253 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 5121
Study 21115098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting with aluminium oxide particles followed by silane coupling agent
Number of subjects: 30
Study 21115098 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion in 9.6% hydrofluoric acid gel for 60 s and silanization for 60 s
Number of subjects: 30
Study 21115098 — intervention group
Group type: COMPARATOR
Intervention: No surface treatment (Control)
Number of subjects: 30
Study 19814804 — intervention group
Group type: EXPERIMENTAL
Intervention: EPHX2 K55R polymorphism in CHD patients after PCI
Number of subjects: 706
Study 19814804 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without CHD)
Number of subjects: 706
Study 18046883 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 332510280
Study 18046883 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-channel blockers (CCBs)
Number of subjects: 332510280
Study 18046883 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-1-blockers (A1Bs)
Number of subjects: 332510280
Study 18046883 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-2 agonists (A2Ags)
Number of subjects: 332510280
Study 14738560 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b plus Thymosin-alpha 1 (900 microg/m2 body surface area)
Number of subjects: 41
Study 14738560 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha 2b alone
Number of subjects: 41
Study 11601508 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 10% dextran 40
Number of subjects: 150
Study 11601508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 9240678 — intervention group
Group type: EXPERIMENTAL
Intervention: Wallstent with periprocedural heparin
Number of subjects: 24
Study 9240678 — intervention group
Group type: EXPERIMENTAL
Intervention: Wallstent without periprocedural heparin
Number of subjects: 24
Study 9240678 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmaz stent with periprocedural heparin
Number of subjects: 24
Study 9240678 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmaz stent without periprocedural heparin
Number of subjects: 24
Study 8250191 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 50
Study 2955033 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinyl oestradiol daily (OC)
Number of subjects: 0
Study 2955033 — intervention group
Group type: COMPARATOR
Intervention: Control period
Number of subjects: 0
Study 30357434 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychedelic truffles (microdose)
Number of subjects: 0
Study 27474356 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (2-30 mg single administration)
Number of subjects: 90
Study 27474356 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (2.5-10 mg multiple administration)
Number of subjects: 90
Study 27474356 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (up to 30 mg single administration and up to 10 mg maintenance dose)
Number of subjects: 90
Study 24456422 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PGDS
Number of subjects: 120
Study 24456422 — intervention group
Group type: EXPERIMENTAL
Intervention: OPG
Number of subjects: 120
Study 24456422 — intervention group
Group type: EXPERIMENTAL
Intervention: OPN
Number of subjects: 120
Study 24456422 — intervention group
Group type: EXPERIMENTAL
Intervention: PAPP-A
Number of subjects: 120
Study 22470524 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor sequence learning task (MST) performance in patients with obstructive sleep apnea
Number of subjects: 31
Study 22470524 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor sequence learning task (MST) plateau performance in patients with obstructive sleep apnea
Number of subjects: 31
Study 21054614 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-based, personal risk network-focused HIV prevention intervention
Number of subjects: 227
Study 18350391 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (six 20-minute sessions)
Number of subjects: 24
Study 18350391 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control condition
Number of subjects: 24
Study 16310197 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (300 ml for 15 days)
Number of subjects: 20
Study 16310197 — intervention group
Group type: EXPERIMENTAL
Intervention: White wine (300 ml for 15 days)
Number of subjects: 20
Study 16310197 — intervention group
Group type: COMPARATOR
Intervention: Control (no alcohol for 15 days)
Number of subjects: 20
Study 12794960 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 0
Study 10762178 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg x kg(‐1) over 1 h, followed by 5.4 mg x kg(‐1) x h(‐1) for 23 h)
Number of subjects: 106
Study 10762178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (0.015 mg x kg(‐1) x h(‐1) for 2 h followed by 0.03 mg x kg(‐1)h(‐1) for 7 days)
Number of subjects: 106
Study 10762178 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Methylprednisolone and Nimodipine
Number of subjects: 106
Study 10762178 — intervention group
Group type: COMPARATOR
Intervention: No medical treatment (Control group)
Number of subjects: 106
Study 8819541 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-free diet
Number of subjects: 22
Study 8819541 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted diet (atopic group)
Number of subjects: 22
Study 1483668 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin sulfate (6 g per os)
Number of subjects: 39
Study 1483668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 1483668 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin sulfate
Number of subjects: 39
Study 3872075 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular stimulation
Number of subjects: 30
Study 3872075 — intervention group
Group type: COMPARATOR
Intervention: Visual stimulation
Number of subjects: 30
Study 3872075 — intervention group
Group type: COMPARATOR
Intervention: Combined vestibular and visual stimulation
Number of subjects: 30
Study 29363339 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led, stage-matched intervention
Number of subjects: 0
Study 29363339 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (UCG)
Number of subjects: 0
Study 29126314 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 29126314 — intervention group
Group type: COMPARATOR
Intervention: Standard single-agent therapy
Number of subjects: 0
Study 27154847 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim-stimulated marrow (G-BM)
Number of subjects: 230
Study 27154847 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim-mobilized peripheral blood (G-PB)
Number of subjects: 230
Study 24085401 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched chain amino acids-related metabolites
Number of subjects: 73
Study 23241329 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin
Number of subjects: 182
Study 23241329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 21056464 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (1.5 mg twice daily increasing to 6 mg twice daily) as an adjunct to usual care with haloperidol
Number of subjects: 104
Study 21056464 — intervention group
Group type: COMPARATOR
Intervention: Placebo as an adjunct to usual care with haloperidol
Number of subjects: 104
Study 17785930 — intervention group
Group type: EXPERIMENTAL
Intervention: Efonidipine 20‐60 mg twice daily
Number of subjects: 21
Study 17785930 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 2.5‐7.5 mg once daily
Number of subjects: 21
Study 15180833 — intervention group
Group type: EXPERIMENTAL
Intervention: Panoptic direct ophthalmoscope (PO)
Number of subjects: 10
Study 15180833 — intervention group
Group type: COMPARATOR
Intervention: Conventional direct ophthalmoscope (CO)
Number of subjects: 10
Study 15180833 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CO and PO
Number of subjects: 10
Study 11178767 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel and clips
Number of subjects: 18
Study 11178767 — intervention group
Group type: COMPARATOR
Intervention: Monopolar electrosurgery and clips
Number of subjects: 18
Study 9710029 — intervention group
Group type: EXPERIMENTAL
Intervention: RBD group
Number of subjects: 61
Study 9710029 — intervention group
Group type: COMPARATOR
Intervention: Non-RBD group
Number of subjects: 61
Study 9710029 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with prior SRI
Number of subjects: 61
Study 9710029 — intervention group
Group type: EXPERIMENTAL
Intervention: RBD association with SRI
Number of subjects: 61
Study 7526676 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (selective beta blocker) for 8 weeks
Number of subjects: 0
Study 7526676 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (not treated with celiprolol)
Number of subjects: 0
Study 2690287 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 0
Study 2690287 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 0
Study 2690287 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 0
Study 2690287 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 0
Study 238256 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorazepate
Number of subjects: 0
Study 238256 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 238256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31822745 — intervention group
Group type: EXPERIMENTAL
Intervention: Young adolescents with macrotrauma (T1)
Number of subjects: 70
Study 31822745 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adolescents with macrotrauma (T1)
Number of subjects: 70
Study 31822745 — intervention group
Group type: COMPARATOR
Intervention: Young adolescents without macrotrauma (T0)
Number of subjects: 70
Study 31822745 — intervention group
Group type: COMPARATOR
Intervention: Older adolescents without macrotrauma (T0)
Number of subjects: 70
Study 27114243 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training on the management of acute agitation
Number of subjects: 26
Study 27114243 — intervention group
Group type: COMPARATOR
Intervention: Didactic-based instruction (control)
Number of subjects: 26
Study 25484317 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (EX)
Number of subjects: 101
Study 25484317 — intervention group
Group type: COMPARATOR
Intervention: Relaxation control (RC)
Number of subjects: 101
Study 23339639 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV) for a median of 3 days (IQR 2 to 8)
Number of subjects: 548
Study 23339639 — intervention group
Group type: COMPARATOR
Intervention: Control ventilation strategy targeting lung recruitment with low tidal volumes and high positive end-expiratory pressure
Number of subjects: 548
Study 23339639 — intervention group
Group type: EXPERIMENTAL
Intervention: HFOV group
Number of subjects: 548
Study 21751904 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus short-term ADT (4 months of total androgen suppression starting 2 months before radiotherapy)
Number of subjects: 1979
Study 21751904 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 1979
Study 21751904 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus short-term ADT
Number of subjects: 1979
Study 19466504 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CIP) at 300 mg twice daily by intravenous drip infusion
Number of subjects: 104
Study 19466504 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin (IPM/CS) at 500 mg twice daily by intravenous drip infusion
Number of subjects: 104
Study 16912265 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 9691
Study 16912265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9691
Study 16225723 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate anaesthetic block
Number of subjects: 90
Study 16225723 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia
Number of subjects: 90
Study 12450637 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (2 mg/day)
Number of subjects: 34
Study 12450637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 10548960 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine
Number of subjects: 0
Study 8703665 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin
Number of subjects: 10
Study 8703665 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 10
Study 2274199 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol + Ketamina
Number of subjects: 43
Study 343993 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% halcinonide applied once daily
Number of subjects: 53
Study 343993 — intervention group
Group type: COMPARATOR
Intervention: 0.05% betamethasone dipropionate cream applied twice daily
Number of subjects: 53
Study 30433893 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum drainage
Number of subjects: 100
Study 30433893 — intervention group
Group type: COMPARATOR
Intervention: Manual drainage
Number of subjects: 100
Study 28633582 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute phenylalanine/tyrosine depletion (APTD) in dim light (10 lux)
Number of subjects: 32
Study 28633582 — intervention group
Group type: COMPARATOR
Intervention: Nutritionally balanced control mixture in dim light (10 lux)
Number of subjects: 32
Study 28633582 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute phenylalanine/tyrosine depletion (APTD) in bright light (3000 lux)
Number of subjects: 32
Study 28633582 — intervention group
Group type: COMPARATOR
Intervention: Nutritionally balanced control mixture in bright light (3000 lux)
Number of subjects: 32
Study 28633582 — intervention group
Group type: EXPERIMENTAL
Intervention: Light × mixture interaction for reaction time to fear
Number of subjects: 32
Study 26538383 — intervention group
Group type: EXPERIMENTAL
Intervention: Not the Ice Cream Van (NTICV)
Number of subjects: 20975
Study 26538383 — intervention group
Group type: EXPERIMENTAL
Intervention: Goddess Demetra (GD)
Number of subjects: 20975
Study 26538383 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20975
Study 23706899 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine treatment
Number of subjects: 0
Study 23706899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19941014 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 30
Study 19941014 — intervention group
Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 30
Study 19941014 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 30
Study 19191743 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH levels (0.3-10.0 mIU/L)
Number of subjects: 489
Study 17045366 — intervention group
Group type: EXPERIMENTAL
Intervention: dTap
Number of subjects: 593
Study 17045366 — intervention group
Group type: COMPARATOR
Intervention: DTaP-IPV
Number of subjects: 593
Study 15492567 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-lumen gastrojejunostomy tube (GJT)
Number of subjects: 36
Study 15492567 — intervention group
Group type: COMPARATOR
Intervention: Routine care of the operating surgeon (Control)
Number of subjects: 36
Study 11550739 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy
Number of subjects: 75
Study 11550739 — intervention group
Group type: COMPARATOR
Intervention: Individual therapy
Number of subjects: 75
Study 11550739 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment conditions
Number of subjects: 75
Study 9586798 — intervention group
Group type: EXPERIMENTAL
Intervention: Older individuals (ARMD, diabetes, and controls)
Number of subjects: 119